Trial Profile
Randomized Study Comparing i.v. Busulfan (Busilvex) Plus Fludarabine (BuFlu) Versus Busilvex Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age ≥ 40 and =<65 Years) With AML in Complete Remission
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Mar 2023
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Fludarabine (Primary) ; Cyclophosphamide
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 13 Dec 2022 Primary endpoint (Transplant-related mortality (TRM)) has been met, as per results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 13 Dec 2022 Results of the long-term analysis comparing busulfan+cyclophosphamide versus busulfan+fludarabine in patients with acute myeloid leukemia, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 28 Sep 2015 Results published in the Lancet Oncology.